European Registry on <i>Helicobacter pylori</i> management (Hp-EuReg): patterns and trends in first-line empirical eradication prescription and outcomes of 5 years and 21 533 patients.

Nyssen, Olga P; Bordin, Dmitry; Tepes, Bojan; Pérez-Aisa, Ángeles; Vaira, Dino; Caldas, Maria; Bujanda, Luis; Castro-Fernandez, Manuel et al. · Gut · 2021

prospective_cohort · Level II

Where this comes from

Abstract

The best approach for <i>Helicobacter pylori</i> management remains unclear. An audit process is essential to ensure clinical practice is aligned with best standards of care. International multicentre prospective non-interventional registry starting in 2013 aimed to evaluate the decisions and outcomes in <i>H. pylori</i> management by European gastroenterologists. Patients were registered in an e-CRF by AEG-REDCap. Variables included demographics, previous eradication attempts, prescribed treatment, adverse events and outcomes. Data monitoring was performed to ensure data quality. Time-trend and geographical analyses were performed. 30 394 patients from 27 European countries were evaluated and 21 533 (78%) first-line empirical <i>H. pylori</i> treatments were included for analysis. Pretreatment resistance rates were 23% to clarithromycin, 32% to metronidazole and 13% to both. Triple therapy with amoxicillin and clarithromycin was most commonly prescribed (39%), achieving 81.5% modified intention-to-treat eradication rate. Over 90% eradication was obtained only with 10-day bismuth quadruple or 14-day concomitant treatments. Longer treatment duration, higher acid inhibition and compliance were associated with higher eradication rates. Time-trend analysis showed a region-dependent shift in prescriptions including abandoning triple therapies, using higher acid-inhibition and longer treatments, which was associated with an overall effectiveness increase (84%-90%). Management of <i>H. pylori</i> infection by European gastroenterologists is heterogeneous, suboptimal and discrepant with current recommendations. Only quadruple therapies lasting at least 10 days are able to achieve over 90% eradication rates. European recommendations are being slowly and heterogeneously incorporated into routine clinical practice, which was associated with a corresponding increase in effectiveness.

Medical subject headings